A number of firms have modified their ratings and price targets on shares of ResMed (NYSE: RMD) recently:

  • 2/5/2018 – ResMed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ResMed exited the second quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. The company achieved solid double-digit global revenue growth in the quarter, led by sales from Software-as-a-Service business as well as mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. Among the recent developments, the company recently informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP device. In the past three months, ResMed has outperformed the broader industry. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising costs and a weak gross margin are other concerns.”
  • 2/2/2018 – ResMed was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $112.00 price target on the stock. According to Zacks, “ResMed exited the second quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. The company achieved solid double-digit global revenue growth in the quarter, led by sales from Software-as-a-Service business as well as mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. Among the recent developments, the company recently informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP device. In the past three months, ResMed has outperformed the broader industry. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising costs and a weak gross margin are other concerns.”
  • 1/23/2018 – ResMed was upgraded by analysts at Northland Securities from an “under perform” rating to a “market perform” rating.
  • 1/23/2018 – ResMed was downgraded by analysts at Macquarie from a “neutral” rating to a “sell” rating.
  • 1/23/2018 – ResMed had its price target raised by analysts at BMO Capital Markets to $90.00. They now have a “market perform” rating on the stock.
  • 1/23/2018 – ResMed was upgraded by analysts at Needham & Company LLC from an “underperform” rating to a “hold” rating.
  • 1/19/2018 – ResMed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry. However, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns.”
  • 1/18/2018 – ResMed was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $99.00 price target on the stock. According to Zacks, “Over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry. However, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns.”
  • 1/11/2018 – ResMed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns. However, over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry.”
  • 1/5/2018 – ResMed was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. They now have a $99.00 price target on the stock. According to Zacks, “Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns. However, over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry.”
  • 12/26/2017 – ResMed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns. However, over the recent past, ResMed has been observed to achieve strong global revenue growth led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry.”

Shares of ResMed Inc. (NYSE:RMD) traded up $0.68 during midday trading on Monday, reaching $91.73. The company’s stock had a trading volume of 663,177 shares, compared to its average volume of 885,025. The company has a market cap of $13,013.51, a price-to-earnings ratio of 45.87 and a beta of 0.92. ResMed Inc. has a 1-year low of $67.04 and a 1-year high of $104.78.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The business had revenue of $601.27 million for the quarter, compared to the consensus estimate of $583.77 million. During the same period last year, the business posted $0.73 EPS. The business’s revenue was up 13.4% compared to the same quarter last year. research analysts expect that ResMed Inc. will post 3.34 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 8th will be issued a $0.35 dividend. The ex-dividend date is Wednesday, February 7th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.53%. ResMed’s dividend payout ratio is presently 70.00%.

In other news, insider James Hollingshead sold 7,019 shares of ResMed stock in a transaction on Monday, November 20th. The stock was sold at an average price of $84.16, for a total value of $590,719.04. Following the transaction, the insider now directly owns 66,409 shares in the company, valued at approximately $5,588,981.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronald R. Taylor sold 4,885 shares of ResMed stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $99.71, for a total value of $487,083.35. Following the completion of the transaction, the director now owns 21,751 shares in the company, valued at $2,168,792.21. The disclosure for this sale can be found here. Insiders sold a total of 49,802 shares of company stock worth $4,824,727 over the last quarter. Company insiders own 1.77% of the company’s stock.

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Receive News & Ratings for ResMed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc and related companies with MarketBeat.com's FREE daily email newsletter.